What IsPT-141 10mg?

PT-141 10mg also called bremelanotide, is sometimes referred to as the female Viagra because the peptide was previously investigated in phase IIb human clinical trials for use in treating female hypoactive sexual desire disorder (HSDD). PT-141 is a melanocortin that binds primarily to melanocortin 4 receptor (MC-4R) and MC-1R. In 2009, PT-141 was also investigated as a treatment for acute hemorrhage. PT-141 is a derivative of another synthetic melanocortin, melanotan 2 (MT-2).

HPLC PT-141 10mgCertificate

MS PT-141 10mgCertificate

PT-141 10mg Research

PT-141 and Sexual Arousal

PT-141 10mg is a unique peptide in that it stimulates the MC-4R, which is known to produce sexual arousal in the central nervous system and influence sexual behavior[1], [2]. Studies in mice have shown that agonist binding to MC-4R causes sexual arousal and increased copulation in both males and females [3], [4]. Because PT-141 works via a different mechanism than drugs like Viagra, it is possible to treat sexual arousal disorders in both men and women that stem from causes other than reduced blood flow to the genitals.

A study of men with erectile dysfunction (ED) who did not respond to sildenafil (Viagra) found that roughly one third experienced adequate erection for sexual intercourse with PT-141 (administered via nasal spray). There was also a strong dose-dependent response in the trial, indicating that PT-141 is indeed effective in certain cases[]. This suggests that PT-141 could offer insight into correcting ED in settings where sildenafil has failed and may offer insight into central causes of hypoactive sexual desire.

Interestingly, PT-141 was pulled from clinical trials before it reached approval for use in women suffering from HSDD. This is despite signs that the drug increased the number of satisfying sexual events per month and decreased female sexual distress scores in a statistically significant manner without any substantial side effects[0]. Many experts who treat female sexual dysfunction (FSD) were dismayed to find the peptide was not being advanced despite positive results. They point to a lack of established endpoints for trials of FSD and socio-cultural biases against women’s sexual health as the primary roadblocks that are inhibiting approval of what they see as much-needed therapies[7]. They hope that greater attention will be given to the topic and that the FDA will establish more concrete guidelines for evaluating therapies like PT-141 that can offer benefit. These experts also expressed dismay that the pharmacological treatments were not tested in conjunction with other established means of treating sexual dysfunction as they believe that the combination may prove synergistic and that peptides like PT-141 may be useful for overcoming initial barriers and jump-starting psychological treatment modalities.

In 2017, partly in response to the outcry against the cessation of earlier trials, Phase II Reconnect trials were launched using subcutaneous injections of PT-141 for FSD. The newest version of PT-141, called Rekynda, may soon be available for use in the United States. It would be legal to use PT-141 off-label, at that point, to treat both male and female sexual dysfunction [8]. These new trials have relied on the kind of modified endpoints that experts in FSD have touted as beneficial to seeing these kinds of treatments approved

PT-141 and Hemorrhage

In 2009, PT-141 was modified slightly and investigated as a potential treatment for hemorrhagic shock. Because PT-141 binds to both MC-1R and MC-4R, it reduces ischemia and protects tissues against inadequate blood supply in the setting of hypovolemic (hemorrhagic) shock. The drug, when administered intravenously, does not produce substantial side effects. It was last in phase IIb trials. The modified version of PT-141 is referred to as PL-6983.

PT-141 and Infection

The MC-1R has been found, in a rat model of a specific fungal infection, to possess important anti-fungal and anti-inflammatory properties [9]. This is of particular importance because current anti-fungals are limited in terms of their mechanism of action and all produce serious and treatment-limiting side effects in certain patients. Having an alternative to use in the treatment of fungal infections could reduce morbidity and mortality substantially, especially in patients with immune compromise.

PT-141 and Cancer

The MC-1R receptor is an important stimulus of DNA repair pathways and thus is of interest in cancer treatment and prevention [10]. Research shows that people with variants of MC-1R are at increased risk for both basal cell and squamous cell carcinoma [11]. Altered PT-141 may be able to correct the problems experienced as a result of these variants and prevent or treat these cancers.

Research Directions

Right now, PT-141 has received widespread and intense attention as a treatment for sexual dysfunction. There is, however, a great deal of potential research outside of sexual dysfunction and hemorrhage that PT-141 could be applied to. For instance, MC-4R is well-known to be defective or missing in certain cases of obesity and may account for as much as 6% of all cases of early-onset obesity. PT-141 offers a unique means of exploring this particular cause of obesity and potentially illustrating a pathway for intervention. MC-1R plays roles in both pain and inflammation as well as kidney pathology and the spread of infection. There is a plethora of available research that PT-141 could help to shed light on.

PT-141 exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. PT-141 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy PT-141 if you are a licensed researcher.

PT-141 (Bremelanotide) 10mg – Frequently Asked Questions

1. What is PT-141?

PT-141, also known as bremelanotide, is a synthetic peptide used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin receptors in the brain, which are involved in sexual arousal and desire.

2. What is the recommended dosage?

The standard effective dose is 1mg to 2mg (10–20 units), injected subcutaneously in the abdomen or thigh about 30–60 minutes before sexual activity. A 10mg vial typically provides 10 doses.

3. How often can I use PT-141?

It is recommended to administer PT-141 no more than once every 72 hours (every 3 days). This equates to up to 8 doses per month. Exceeding this frequency may increase the risk of side effects.

4. How should I store PT-141?

Store PT-141 in a cool, dry place at room temperature, away from light. Avoid freezing. Reconstituted solutions should be used within 30 days and stored in the refrigerator.

5. What are the common side effects?

Common side effects include:

• Nausea

• Flushing (hot flashes)

• Headache

• Injection site reactions (pain, redness, swelling)

• Dizziness or fatigue

These side effects are typically mild and transient.

6. Are there any serious side effects?

Serious side effects may included

• Severe or persistent nausea

• High blood pressure (severe headache, blurred vision, pounding in your neck or ears)

• Slow heartbeats

• Darkening of the skin, especially on the face, gums, or breastsOptimal 

If you experience any of these symptoms, contact your healthcare provider immediately.

7. Who should not use PT-141?

PT-141 is contraindicated for:Wikipedia+4help.

• Individuals with uncontrolled high blood pressure or cardiovascular disease

• Postmenopausal women

• Men

• Individuals with hypersensitivity to bremelanotide or any of its components

It should not be used to improve sexual performance in individuals without HSDD.

8. Can I use PT-141 with other medications?

PT-141 may interact with certain medications, such as naltrexone and indomethacin, by reducing their oral absorption. Consult your healthcare provider before combining PT-141 with other treatments.

9. How soon can I expect results?

Most individuals begin to notice the effects of PT-141 within 2 to 4 hours after administration. The duration of effect can vary among individuals.

10. Where can I obtain PT-141?

PT-141 is available only through a healthcare provider’s prescription. It is not approved for over-the-counter use. In some regions, it may be available through specialized clinics or pharmacies that offer peptide therapies.

Vendor: PeptideNationUSA